81.38
-1.52%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About DiaSorin SpA
Its shares trade on Borsa Italiana under the ticker DIA.MI. It has been listed since 19 July 2007. In the fiscal year to 31 December 2025, it reported revenue of €1.20bn and net income of €155.6m. At that date it held total assets of €2.87bn and shareholders' equity of €1.58bn.
DiaSorin SpA engages in the development, production, and marketing of reagent kits for in vitro diagnostics. The company is headquartered in Saluggia, Vercelli. The company went IPO on 2007-07-19. The firm specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The firm develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company’s business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. The company operates through ELISA immunodiagnostic business portfolio.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 19 Jul 2007
- Employees
- 1,939
- Website
- diasorin.com ↗
Leadership
Pay as last reported
- Mr. Michele DenegriNon-Executive Chairman of the Board€400,000
- Mr. Carlo RosaChief Executive Officer, Executive Director, General Manager, since 1998€1.8m
- Mr. Giancarlo BoschettiNon-Executive Vice Chairman of the Board€155,000
- Mr. Piergiorgio PedronChief Financial Officer
- Dr. Chen EvenExecutive Director, Chief Commercial Officer, since 2007€937,650
- Mr. Andre BallesterLead Independent Director€55,000
- Mr. Stefano AltaraNon-Executive Director€40,000
- Mr. Luca MelindoNon-Executive Director€40,000
- Mr. Diego PistoneNon-Executive Director€40,000
- Mrs. Fiorella AltrudaNon-Executive Independent Director€40,000
- Mr. Franco MoscettiNon-Executive Independent Director€45,000
- Ms. Giovanna ParraviciniNon-Executive Independent Director€50,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 60
- Environment
- 51
- Social
- 81
- Governance
- 48
- Direct emissions (scope 1)
- 3,894 t
- Energy emissions (scope 2)
- 15,001 t
- Women in the workforce
- 43.59293%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- DiaSorin SpA has several strengths that contribute to its success in the market.
Weaknesses
- Despite its strengths, DiaSorin SpA also faces certain weaknesses that need to be addressed.
Opportunities
- DiaSorin SpA can leverage various opportunities to further expand its business and market position.
Threats
- DiaSorin SpA faces certain threats that could impact its performance and competitiveness.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.